This library gathers the ibogaine research we cite on this site. Each card gives the full reference, a link to the original, the type of study, how strong its evidence is and, always, its limits. The summaries are ours. The work belongs to its authors, and the original is one click away.
Evidence levels: Level 1 · Systematic review or meta-analysis; Level 2 · Randomized controlled trial; Level 3 · Prospective study in people, no control group; Level 4 · Retrospective study, survey, case series or case report; Level 5 · Animal or laboratory study; Background · Review, guideline, perspective or registry. What these levels mean
General research
- MAPS Ibogaine Investigator's Brochure (July 2026) · 2026 · Background · Free to read (report). The most complete single summary of ibogaine science, from pharmacology to the safety record.
- Stanford MISTIC study (2024) · 2024 · Level 3 · Open access (CC BY). Thirty veterans with brain injury; large one-month drops in disability, PTSD, depression and anxiety; no control group.
- MISTIC 12-month follow-up (2026) · 2026 · Level 3 · Open access. Most gains held at a year, but most participants had also used other psychedelics.
- MISTIC subjective-experience study (2026) · 2026 · Level 4 · Open access. Four themes in what the veterans wrote about the experience.
- Molecules scoping review (2026) · 2026 · Background · Open access. A current overview of ibogaine's promise and its heart risk.
- Köck systematic review (2022) · 2022 · Level 1 · Subscription (abstract free). Twenty-four human studies, 705 people, two randomized.
- Brown & Alper, opioid outcomes in Mexico (2018) · 2018 · Level 3 · Free to read. A strong early effect on withdrawal, then gradual relapse over a year.
- Ibogaine trials on ClinicalTrials.gov (2026 snapshot) · 2026 · Background · Registry. Every registered ibogaine study and its status on the date we checked.
How ibogaine works
- Nicolas, reward-system recovery (2025) · 2025 · Background · Open access. A hypothesis: ibogaine may help reward circuits recover across diagnoses.
- Acuña et al., plasticity in adult mice (2026) · 2026 · Level 5 · Open access. In adult mice, ibogaine reopened a form of plasticity normally limited to youth.
- Glue et al., noribogaine in healthy volunteers (2015) · 2015 · Level 2 (Phase 1 safety trial, healthy volunteers) · Subscription (abstract free). Low doses were well tolerated; noribogaine's half-life was one to two days (28 to 49 hours), so it stays in the body for several days.
Heart and safety
- GITA clinical guidelines (2016) · 2016 · Background · Free to read. The reference protocol for ibogaine detox, written before fentanyl and 7-OH were common.
Further reading (not summarized)
Sources we cite but do not summarize, because they are news, books, abstracts, preprints or work we have not yet read in full. Each links to its original.
- Stanford News. Explainer on the Stanford ibogaine study in veterans, May 2024. news.stanford.edu · News
- De Rienzo P, Beal D, et al. Report on the Staten Island Project: The Ibogaine Story. Brooklyn, NY: Autonomedia; 1997. · Book
- Brackenridge P. Ibogaine therapy in the treatment of opiate dependency. Drugs Alcohol Today. 2010;10(4):20-25. DOI · Practitioner essay
- Tatarsky A, ed. Harm Reduction Psychotherapy: A New Treatment for Drug and Alcohol Problems. Northvale, NJ: Jason Aronson; 2002. · Book (not about ibogaine; relevant to preparation and aftercare)
- Bentura M, Reyes A, Falasco G, et al. Comparison of brain metabolism before, during and after treatment with ibogaine and noribogaine using [18F]FDG PET. J Nucl Med. 2024;65(suppl 2):242210. Journal page · Conference abstract, rat study
- Ali S, Tian X, Cunningham KA, Zhou J. Old dog, new tricks: ibogaine and its analogs as potential neurotherapeutics. J Med Chem. 2025;68(18):18744-18751. DOI · PMC · Not yet read in full
- Tabaac, Carhart-Harris & Yung. Case series on iboga root-bark microdosing in brain injury. Front Pharmacol. 2026;17. DOI · Not yet read in full
- Fonzo. Commentary. Biol Psychiatry Cogn Neurosci Neuroimaging. 2026. DOI · Not yet read in full
- Stanford default-mode-network study. medRxiv, 2026. DOI · Preprint, not peer-reviewed
How we use sources
This library summarizes published research so you can find and read the original. We follow six rules.
- We link to the original. Every card links to the source's DOI, PubMed, PubMed Central or the publisher's own page. We do not host, upload or mirror articles or books.
- Summaries are in our own words. They describe what a source reports and its limits. They do not replace reading it.
- Quotations are short. Under 25 words, in quotation marks, attributed, with the page or section.
- Full texts, figures and tables appear here only when the publisher's licence allows it (for example CC BY or CC0), with the credit the licence requires, or with the rights holder's written permission.
- We never link to unauthorized copies of anyone's work.
- Corrections. If you are an author or publisher and think we have described your work inaccurately, or used it beyond these rules, write to info@ibogaquest.com. We will review it and correct or remove it within 14 days.
Reviewed by the IbogaQuest medical team · Last reviewed 10 October 2026
IbogaQuest is a treatment centre that provides ibogaine. We have no role in the studies summarized here and receive no funding from their authors. Each summary is reviewed by a physician and dated. This library is information, not medical advice.